Mar 20, 2020
National Kidney Foundation Honors Janssen Pharmaceutical Companies of Johnson & Johnson with 2020 Corporate Innovator Award
Nov 09, 2019
New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA® (canagliflozin) are Consistent Across Various Levels of Kidney Function
Oct 01, 2019
Johnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial
Sep 20, 2019
XARELTO® (rivaroxaban) Reduces Recurrent Blood Clots and Total Medical Costs in Morbidly Obese Patients
Aug 26, 2019
Johnson & Johnson To Appeal Flawed Opioid Judgment in Oklahoma
May 18, 2019
New Real-World Evidence Highlights Need for Interventions to Improve Outcomes for Patients Who Have Been Diagnosed with Major Depressive Disorder (MDD) and Suicide Ideation or Attempt
Apr 12, 2019
BALVERSA(TM) (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations
Mar 06, 2019
Icahn School of Medicine Dean Dennis Charney, MD, Co-Invented a Patented Method of Treating Patients with Treatment-Resistant Depression
Jan 07, 2019
Winterlight Labs, Inc. Enters Collaboration with Johnson & Johnson Innovation to Develop a Digital Biomarker for Diagnosis of Early Stage Alzheimer's Disease
Dec 13, 2018
Janssen Signs Results-Based Contract with Oklahoma Health Care Authority (OHCA) for its Long-Acting Injectable Schizophrenia Medicines
Nov 02, 2018
Janssen Issues Voluntary Nationwide Recall for one lot of ORTHO-NOVUM® 1/35 and two lots of ORTHO-NOVUM® 7/7/7 Due to Incorrect Veridate® Dispenser Instructions
Oct 30, 2018
U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Oct 29, 2018
New Data Presented at Psych Congress 2018 Sheds Light on the Significant Economic Burden of Treatment-Resistant Depression Amongst U.S. Veterans
Oct 11, 2018
U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
Oct 04, 2018
Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection
Apr 16, 2018
Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases
Mar 08, 2018
Judge's Order Sets 1,200 Xarelto Product Liability Lawsuits for Separate Jury Trials
Jan 04, 2018
Beacon Discovery announces multi-year GPCR-focused drug discovery collaboration with Janssen Pharmaceuticals
Jan 03, 2018
Landmark Schizophrenia Data That Bring Hope in Breaking the Cycle of Hospitalization and Incarceration Receive FDA Approval for Inclusion in INVEGA SUSTENNA® (paliperidone palmitate) Label
Jan 02, 2018
Lawsuits Filed Against J&J Related to its Drug Invokana